Skip to main content

Overactive Bladder Syndrome

6
Pipeline Programs
11
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
4
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
2
DarifenacinPhase 31 trial
DarifenacinPhase 31 trial
Active Trials
NCT00170755Completed718Est. Jan 2005
NCT00171145Completed445Est. Dec 2004
Pfizer
PfizerNEW YORK, NY
2 programs
2
SPM 907Phase 31 trial
SPM 907Phase 31 trial
Active Trials
NCT00220363CompletedEst. Feb 2005
NCT00220376CompletedEst. Jul 2007
Imbrium Therapeutics
1 program
1
V117957Phase 11 trial
Active Trials
NCT06024642Completed51Est. May 2024
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
1
V117957Phase 1
Axonics
AxonicsCA - Irvine
1 program
Axonics SystemN/A1 trial
Active Trials
NCT05543382Terminated31Est. Dec 2024
Takeda
TakedaTOKYO, Japan
1 program
PropiverineN/A1 trial
Active Trials
NCT02024945Completed437Est. Dec 2011
URO-1
URO-1NC - Greensboro
1 program
Repris NeedleN/A1 trial
Active Trials
NCT04982120Unknown40Est. Jul 2022
Medtronic
MedtronicNJ - Phillipsburg
1 program
Sacral neuromodulationN/A1 trial
Active Trials
NCT05313984Completed93Est. Dec 2021
Laborie
LaborieNH - Portsmouth
1 program
percutaneous tibial nerve stimulationN/A1 trial
Active Trials
NCT03559946Terminated5Est. Mar 2020
Novartis
NovartisBASEL, Switzerland
1 program
DarifenacinPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozDarifenacin
PfizerSPM 907
PfizerSPM 907
SandozDarifenacin
Imbrium TherapeuticsV117957
AxonicsAxonics System
URO-1Repris Needle
Laboriepercutaneous tibial nerve stimulation
MedtronicSacral neuromodulation
TakedaPropiverine

Clinical Trials (10)

Total enrollment: 1,820 patients across 10 trials

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Start: Apr 2004Est. completion: Dec 2004445 patients
Phase 3Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

Start: Apr 2004Est. completion: Jul 2007
Phase 3Completed

A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Start: Jan 2004Est. completion: Feb 2005
Phase 3Completed

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Start: Apr 2002Est. completion: Jan 2005718 patients
Phase 3Completed

Study of V117957 in Overactive Bladder Syndrome

Start: Jun 2022Est. completion: May 202451 patients
Phase 1Completed
NCT05543382AxonicsAxonics System

Cycling Study With the Axonics System

Start: Aug 2022Est. completion: Dec 202431 patients
N/ATerminated
NCT04982120URO-1Repris Needle

Use of Repris Needle in Bladder Injection

Start: Oct 2018Est. completion: Jul 202240 patients
N/AUnknown
NCT03559946Laboriepercutaneous tibial nerve stimulation

Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol

Start: Jun 2018Est. completion: Mar 20205 patients
N/ATerminated
NCT05313984MedtronicSacral neuromodulation

OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation.

Start: Mar 2018Est. completion: Dec 202193 patients
N/ACompleted

Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome

Start: Nov 2010Est. completion: Dec 2011437 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.